TY - JOUR
T1 - A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection
AU - Beaudoin-Bussières, Guillaume
AU - Chen, Yaozong
AU - Ullah, Irfan
AU - Prévost, Jérémie
AU - Tolbert, William D.
AU - Symmes, Kelly
AU - Ding, Shilei
AU - Benlarbi, Mehdi
AU - Gong, Shang Yu
AU - Tauzin, Alexandra
AU - Gasser, Romain
AU - Chatterjee, Debashree
AU - Vézina, Dani
AU - Goyette, Guillaume
AU - Richard, Jonathan
AU - Zhou, Fei
AU - Stamatatos, Leonidas
AU - McGuire, Andrew T.
AU - Charest, Hughes
AU - Roger, Michel
AU - Pozharski, Edwin
AU - Kumar, Priti
AU - Mothes, Walther
AU - Uchil, Pradeep D.
AU - Pazgier, Marzena
AU - Finzi, Andrés
N1 - Copyright © 2022. Published by Elsevier Inc.
PY - 2022/2/15
Y1 - 2022/2/15
N2 - Emerging evidence indicates that both neutralizing and Fc-mediated effector functions of antibodies contribute to protection against SARS-CoV-2. It is unclear whether Fc-effector functions alone can protect against SARS-CoV-2. Here, we isolated CV3-13, a non-neutralizing antibody, from a convalescent individual with potent Fc-mediated effector functions. The cryoelectron microscopy structure of CV3-13 in complex with the SARS-CoV-2 spike reveals that the antibody binds from a distinct angle of approach to an N-terminal domain (NTD) epitope that only partially overlaps with the NTD supersite recognized by neutralizing antibodies. CV3-13 does not alter the replication dynamics of SARS-CoV-2 in K18-hACE2 mice, but its Fc-enhanced version significantly delays virus spread, neuroinvasion, and death in prophylactic settings. Interestingly, the combination of Fc-enhanced non-neutralizing CV3-13 with Fc-compromised neutralizing CV3-25 completely protects mice from lethal SARS-CoV-2 infection. Altogether, our data demonstrate that efficient Fc-mediated effector functions can potently contribute to the in vivo efficacy of anti-SARS-CoV-2 antibodies.
AB - Emerging evidence indicates that both neutralizing and Fc-mediated effector functions of antibodies contribute to protection against SARS-CoV-2. It is unclear whether Fc-effector functions alone can protect against SARS-CoV-2. Here, we isolated CV3-13, a non-neutralizing antibody, from a convalescent individual with potent Fc-mediated effector functions. The cryoelectron microscopy structure of CV3-13 in complex with the SARS-CoV-2 spike reveals that the antibody binds from a distinct angle of approach to an N-terminal domain (NTD) epitope that only partially overlaps with the NTD supersite recognized by neutralizing antibodies. CV3-13 does not alter the replication dynamics of SARS-CoV-2 in K18-hACE2 mice, but its Fc-enhanced version significantly delays virus spread, neuroinvasion, and death in prophylactic settings. Interestingly, the combination of Fc-enhanced non-neutralizing CV3-13 with Fc-compromised neutralizing CV3-25 completely protects mice from lethal SARS-CoV-2 infection. Altogether, our data demonstrate that efficient Fc-mediated effector functions can potently contribute to the in vivo efficacy of anti-SARS-CoV-2 antibodies.
KW - Animals
KW - Antibodies, Neutralizing/therapeutic use
KW - Antibodies, Viral/chemistry
KW - Antibody-Dependent Cell Cytotoxicity
KW - COVID-19 Serotherapy
KW - COVID-19/mortality
KW - Disease Models, Animal
KW - Epitopes
KW - Humans
KW - Immunization, Passive/mortality
KW - Immunoglobulin Fab Fragments/chemistry
KW - Immunoglobulin Fc Fragments/genetics
KW - Mice
KW - Protein Binding
KW - Protein Conformation
KW - SARS-CoV-2/immunology
KW - Spike Glycoprotein, Coronavirus/chemistry
UR - http://www.scopus.com/inward/record.url?scp=85124153861&partnerID=8YFLogxK
U2 - 10.1016/j.celrep.2022.110368
DO - 10.1016/j.celrep.2022.110368
M3 - Article
C2 - 35123652
AN - SCOPUS:85124153861
SN - 2211-1247
VL - 38
SP - 110368
JO - Cell Reports
JF - Cell Reports
IS - 7
M1 - 110368
ER -